Expanding the scope of personalized medicine and clinical diagnostics…

Biomarker testing is now a powerful tool in personalized medicine. Presently, the most promising tests can detect multiple biomarkers in a single assay, providing a more accurate picture of a disease state compared to when a single biomarker is examined. As a result, clinical researchers must now characterize broad sets of biomarkers that may play significant roles in disease diagnosis, prognosis and treatment. To assist in this investigation, new multiplex tools are needed that can be easily adapted to the various stages of biomarker research.

Translating biomarker discoveries from the lab to the clinic…

Our flow-through technologies (Flow-Through Microarrays and Real Time Diffractive Optics) are designed to provide assay developers with the solutions they need for the rapid translation of their discoveries into diagnostic tests; whether it is to discover new sets of protein or RNA biomarkers in the lab, or to develop novel multiplex assays, or to validate these assays on large numbers of patient samples. In addition, our flow-through technologies perform each assay with an eye on future applications in a central laboratory testing facility or as a point of care test. Tools can be provided to the developer for their own use or alternatively, Axela scientists can deliver a completed diagnostic to customer specifications.

Creating the tools that simplify multiplex biomarker testing...

  • Both protein or nucleic acid microarrays (up to 150 markers in triplicate)
  • User defined multiplex immunoassays and protein arrays using panelPlus™ technology (1 to 12-plex)
  • Rapid results (10 minutes to about 1 hour)
  • Small sample sizes (5 uL or less)
  • Flexible sample types (serum, lysates, FFPE, etc)
  • Broad dynamic range (up to 7 logs)
  • High sensitivity (low pg/mL)
  • Hands-off automation (“Set and Forget”)
  • Label free or amplified assays
  • Real time or end point results
  • Decentralized testing compatible format

Axela is currently applying its flow-through technologies to the following general areas of clinical research: